SCF and TLR4 ligand cooperate to augment the tumor-promoting potential of mast cells Jing-Jing WeiChuan-Wang SongZuo-Hua Feng Original article 30 August 2011 Pages: 303 - 312
Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients Sebastian OchsenreitherAlberto FusiUlrich Keilholz Original article 07 September 2011 Pages: 313 - 322
Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma Jingping SunGabriela P. LawRobert J. McKallip Original article 08 September 2011 Pages: 323 - 334
Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer Shao-Bo YangYun DuPing-Chang Yang Original Article 13 September 2011 Pages: 335 - 342
Design of immunogenic and effective multi-epitope DNA vaccines for melanoma Hyun-Il ChoEsteban Celis Original article 14 September 2011 Pages: 343 - 351
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome Yingzi GeChristoph DomschkeFlorian Schuetz Original article 14 September 2011 Pages: 353 - 362
In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging Mauro ProvincialiAlessandra BaruccaArianna Smorlesi Original article 16 September 2011 Pages: 363 - 371
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients Osama E. RahmaEd AshtarSamir N. Khleif Original article 17 September 2011 Pages: 373 - 384
Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens Bianca AltvaterSibylle PschererClaudia Rossig Original article 18 September 2011 Pages: 385 - 396
Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice Angelos D. GritzapisIoannis F. VoutsasConstantin N. Baxevanis Original article 18 September 2011 Pages: 397 - 407
Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions Toshitatsu OginoHideya OnishiMitsuo Katano Original article 20 September 2011 Pages: 409 - 424
Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells Helen ConroyKaren C. GalvinKingston H. G. Mills Short communication 23 December 2011 Pages: 425 - 431
Advances in cellular therapy: 6th international symposium on the clinical use of cellular products, March 24 and 25, 2011, Erlangen, Germany Evelyn UllrichJacobus BoschArmin Gerbitz Meeting report 27 December 2011 Pages: 433 - 443
A rebuttal to the potential anti-tumour benefit of Helicobacter pylori-induced neutrophil-activating protein Jannis KountourasChristos ZavosStergios A. Polyzos Letter to the Editors 08 November 2011 Pages: 445 - 446
HP-NAP new therapy for bladder cancer: numquam periculum sine periculo vincitur Gaia CodoloMatteo FassanMarina de Bernard Letter to the editors 12 November 2011 Pages: 447 - 448
Response to the rebuttal letter of Kountouras and colleagues regarding the paper by Codolo et al. ‘HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response’ Andrew M. JacksonHester A. Franks Letter to the editors 12 November 2011 Pages: 449 - 451
